Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK228 in relapsed lymphoma
NCT02727777Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sapanisertib in lymphoma (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response Assessment at 1 year. Started Mar 2017; status: terminated.
02
Drugs
sapanisertib
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT02727777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727777.